We hypothesized that cytokines influence luteal angiogenesis in mares, while angiogenic factors themselves can also regulate luteal secretory capacity. Therefore, the purpose of this study was to evaluate the role of cytokines-tumor necrosis factor alpha (TNF), interferon gamma (IFNG) and Fas ligand (FASL)-on in vitro modulation of angiogenic activity and mRNA level of vascular endothelial growth factor A (VEGF), its receptor VEGFR2, thrombospondin 1 (TSP1), and its receptor CD36 in equine corpus luteum (CL) throughout the luteal phase. After treatment, VEGF protein expression was determined in midluteal phase (mid) CL cells. The role of VEGF on regulation of luteal secretory capacity was assessed by progesterone (P 4 ) and prostaglandin E 2 (PGE 2 ) production and by mRNA levels for steroidogenic enzymes 3-beta-hydroxysteroid dehydrogenase (3betaHSD) and PGE synthase (PGES). In early CL cells, TNF increased angiogenic activity (bovine aortic endothelial cell viability) and VEGF and VEGFR2 mRNA levels and decreased CD36 (real-time PCR relative quantification). In mid-CL cells, TNF increased VEGF mRNA and protein expression (Western blot analysis) and reduced CD36 mRNA levels, while FASL and TNF+IFNG+FASL decreased VEGF protein expression. In late CL cells, TNF and TNF+IFNG+FASL reduced VEGFR2 mRNA, but TNF+IFNG+FASL increased TSP1 and CD36 mRNA. VEGF treatment increased mRNA levels of 3betaHSD and PGES and secretion of P 4 and PGE 2 . In conclusion, these findings suggest a novel auto/paracrine action of cytokines, specifically TNF, on the up-regulation of VEGF for angiogenesis stimulation in equine early CL, while at luteolysis, cytokines down-regulated angiogenesis. Additionally, VEGF stimulated P 4 and PGE 2 production, which may be crucial for CL establishment.
INTRODUCTION
After ovulation, the process of luteinization leads to formation of the corpus luteum (CL), a transient endocrine structure that sustains the luteal phase of the estrous cycle. Vascular development is a crucial step for proliferation and establishment of the CL. As shown previously in the equine CL, a coordinated cycle of vascular and nonvascular growth and regression occurs, involving both cell proliferation and active caspase-3-mediated apoptosis [1] [2] [3] . Moreover, a dynamic balance between luteotrophic and luteolytic forces regulates CL growth, establishment, and regression [4, 5] . Although angiogenesis is distinctly coordinated and wellcharacterized in different functions throughout the body, in the equine CL, the molecular mechanism regulating this process is still not fully understood. Luteinizing hormone (LH) is one of the major regulators of ovarian angiogenesis in several species [6] [7] [8] . Nevertheless, because not all cell types in the CL express LH receptors [9, 10] , other factors such as vasoactive peptides, growth factors, and cytokines might contribute to the control of luteal angiogenesis [11] .
Angiogenesis and inflammation are codependent processes that are well-characterized in different physiologic and pathologic conditions [12] , but their precise cross-talk in the regulation of luteal growth, differentiation, and regression in the mare is yet unknown. In most tissues, endothelial cells are the major targets of cytokine actions during the immune process, particularly in inflammation. Because a large number of microvascular endothelial cells are present in the CL [13, 14] , their responsiveness to cytokines is thought to be important for luteal function [15] . A regulatory role of cytokines in luteal function has been confirmed previously in several species such as human [16] , cattle [17] [18] [19] , and horse [20] . In terms of regulating luteal angiogenesis, cytokines, such as tumor necrosis factor alpha (TNF) or interferon gamma (IFNG), were shown to regulate bovine luteal endothelial cells [21] [22] [23] . Nevertheless, the way these cytokines might regulate angiogenesis in the equine CL is still unknown.
Among several other factors, vascular endothelial growth factor A (VEGF) is recognized as the main promoter of angiogenesis in the CLs of different species, such as the sheep, marmoset monkey, rat, and horse [24] [25] [26] [27] . The high expression of VEGF in the CL during early and midluteal phases in the mare is associated with endothelial cell proliferation [27] . Specifically, VEGF interaction with its receptor (VEGFR2) triggers the signal transduction pathway for stimulating angiogenesis [28, 29] . Conversely, thrombospondin 1 (TSP1) and its receptor CD36 have been described as putative antiangiogenic factors [30, 31] , being associated with inhibition of follicular angiogenesis [32, 33] . Little is known about TSP1 involvement in luteal function regulation, but its participation in angiogenesis regulation together with VEGF has been demonstrated [32, 34] .
Vascular and nonvascular cell dynamics during CL establishment culminate with the consolidation of luteal structure and progesterone (P 4 ) secretion. Therefore, the relationship between events like angiogenesis regulation and immune response should not be dissociated from secretory functionality. Previous in vivo studies in nonhuman primates reported a role of VEGF in the modulation of P 4 secretion by midluteal phase CLs [35] . Thus, we hypothesized that in the mare cytokines may influence luteal angiogenesis and that angiogenic factors themselves may also regulate luteal secretory capacity. Therefore, the goal of this study was to evaluate the role of the cytokines TNF, IFNG, and Fas ligand (FASL) on in vitro modulation of angiogenic activity and mRNA levels of VEGF, its receptor VEGFR2, TSP1, and its receptor CD36 in the mare CL throughout the luteal phase. VEGF protein expression was determined in midluteal phase CL cells after cytokine treatments. The role of VEGF in the regulation of luteal secretory capacity was assessed by progesterone (P 4 ) and prostaglandin E 2 (PGE 2 ) production and mRNA levels of the steroidogenic enzymes 3-betahydroxysteroid dehydrogenase (3bHSD), and PGE synthase (PGES).
MATERIALS AND METHODS

Collection of Equine Corpora Lutea
Luteal tissue and venous blood from the jugular vein were collected postmortem at a local abattoir from randomly selected cyclic Lusitano mares, aged from 3 to 8 years old, from May until the end of August. The mares were euthanized after stunning according to the European Legislation concerning welfare aspects of animal stunning and killing methods (EFSA, AHAW/04-027) and the Portuguese legislation (DL 98/96, Art. 18), and as approved by the Faculty of Veterinary Medicine Ethics Committee.
Soon after euthanasia of the mares, their internal reproductive organs were collected. The ovaries were separated from the oviducts, opened up, and luteal structures were classified as previously described [20, 36] : early luteal phase CL (presence of corpus hemorrhagicum, P 4 . 1 ng/ml, early CL; n ¼ 6), midluteal phase CL (CL associated with follicles 15-20 mm in diameter and P 4 . 6 ng/ml, mid-CL; n ¼ 11), or late luteal phase CL (CL associated with a preovulatory follicle 30-35mm in diameter and P 4 between 1 and 2 ng/ml, late CL; n ¼ 6). Later, luteal samples were isolated and placed in culture medium M199 (M2154; Sigma-Aldrich) with 0.1% bovine serum albumin (BSA) (735078; Roche Diagnostics GmbH Mannheim), 20 lg/ml gentamicin (G1397; Sigma), and 250 lg/ml amphotericin (A2942; Sigma), and transported on ice to the laboratory for in vitro studies.
Isolation and Culture of Luteal Cells
Luteal cell isolation followed the methodology described previously [20] . Briefly, after washing the samples several times with sterile 0.1 M phosphate buffer solution (PBS), pH 7.4, connective tissue and blood clots were removed and CLs were minced into small pieces. Enzymatic digestion was performed for 50 min with M-199 with 0.1% (w/v) collagenase (C-0130; Sigma), 0.01% DNase I (D-5025; Sigma), and 0.1% (w/v) BSA. Following digestion, all the collected cells were filtered twice with a cell dissociation Sieve-Tissue Grinder Kit (cd1-1kt; Sigma) through metal wire meshes [20] . After several washing steps (180 3 g centrifugation with M-199 containing 0.1% BSA), erythrocytes were lysed with red blood cell lysis buffer (R7757; Sigma). Cells were then resuspended in Dulbecco modified Eagle medium/Ham F-12 medium (D/F medium; 1:1) (D-8900; Sigma) containing 10% fetal bovine serum (FBS) (26140-079; Gibco) and 20 lg/ml gentamicin. Cell viability, which ranged between 83% to 89% live cells, was assessed by trypan blue exclusion dye (T8154; Sigma). Dispersed luteal cells were then cultured either in 1 ml of D/F medium in 24-well culture plates (142475; Nunc) at a concentration of 2.0 3 10 5 /ml (experiment 1) or in 5 ml D/F medium in T25 culture flasks (136196, Nunc) at concentration of 5.0 3 10 6 /ml (experiment 1) with 10% FBS, 250 lg/ ml amphotericin, and 20 lg/ml gentamicin at 378C and 5% CO 2 . A smear of each cell suspension was prepared for histological examination and stained with Diff-Quick (Baxter Scientific) for identification of luteal cells [37] . In early luteal phase CLs, around 40% of the cells were large luteal cells and about 50% were small luteal cells based on histologic features [37] . Midluteal phase CLs consisted of about 65% large luteal cells and 20% small luteal cells, while in late luteal phase CLs 45% were large luteal cells and 35% small luteal cells. Other cell types like endothelial cells and fibroblasts represented approximately 10% of the total cells. Once cells were adherent in a monolayer with a 90%-95% confluence, they were washed with M-199 with 0.1% BSA, and then phenol red-free D/F medium (1:1) (11039; Gibco) with 0.1% BSA, 20 lg/ml gentamicin, and 5 lg/ml transferrin (T1428; Sigma) were added.
Following luteal cell treatments (experiments 1 and 2), conditioned media and cells were collected. After washing with sterile 0.1 M PBS, pH 7.4, cells were scraped (179693; Nunc) and resuspended in either TRIZOL reagent (15596-026; Invitrogen) for mRNA analysis (experiments 1 and 2) or ice-cold homogenization buffer-25 mM Tris-HCl (A3452; Applichem), 300 mM sucrose (S5016; Sigma), 2 mM ethylenediaminetetraacetic acid (E5134; Sigma), and complete protease inhibitor cocktail (1697498; Roche), pH 7.4-for Western blot analysis (experiment 1). The cells and media were then stored at À808C for further experiments.
RNA Isolation and cDNA Synthesis
After treatment (experiments 1 and 2), total RNA was extracted from luteal cells with TRIZOL reagent following the manufacturer's instructions. As described before [20] , after RNA concentration assessment, 1 lg of total RNA was reverse transcribed using Reverse Transcriptase Superscript III enzyme (18080093; Gibco) and oligo (dT) primer (27-7858-01; GE Healthcare).
Real-Time PCR
Real-time PCR assays were performed in a 7300 Real-Time PCR System (Applied Biosystems), using a default thermocycler program for all the genes: a 10-min preincubation at 958C was followed by 40 cycles of 15 sec at 958C and 1 min at 608C. A further dissociation step (15 sec at 958C, 30 sec at 608C, and 15 sec at 958C) ensured the presence of a single product. In each real-time assay, both the target gene and a housekeeping gene b2-microglobulin (B2MG) were run simultaneously, and the reactions were carried out in duplicate wells on a 96-well optical reaction plate (4306737; Applied Biosystems) in 25 ll. Primers for B2MG were previously designed (Table 1 ) [20] . After the run, PCR product specificity was confirmed in a 2.5% agarose (BIO-41025; Bioline) gel. Real-time results were analyzed with the real-time PCR Miner algorithm [38] .
Experiment 1. Cytokine Effects on Production of Angiogenic and Antiangiogenic Factors
Cell culture treatment with cytokines. Dose assessment for the cytokines used was determined previously [20] . Following the stabilization period, cells from different luteal stages (early CL, n ¼ 6; mid-CL, n ¼ 6; and late CL, n ¼ 6) were incubated either in 24-well plates (see Endothelial cell viability assay and Cytokine effects on VEGF, VEGFR2, TSP1, and CD36 mRNA transcription) or in T25 flasks (see Western blot analysis of VEGF) for 24 h in a 5% CO 2 in an air chamber with 1) no exogenous cytokines (negative control), 2) TNF (10 ng/ ml), 3) IFNG (10 ng/ml), 4) FASL (10 ng/ml), or 5) TNFþIFNGþFASL (each 10 ng/ml). After the incubation, cell-conditioned media were frozen atÀ808C for further studies on angiogenic activity (see Endothelial cell viability assay). Cells were scraped and kept frozen for evaluation of angiogenic and antiangiogenic mRNA transcription (experiment 1.3) and quantification of proteins (see Western blot analysis of VEGF).
Endothelial cell viability assay. The effect of different cell treatments (i.e., control, TNF, IFNG, FASL, or TNFþIFNGþFASL) on angiogenic activity in early, mid-, and late CL luteal-conditioned media (LCM) was indirectly assessed after viability evaluation of bovine aortic endothelial cells (BAEC; kindly donated by Dr. D.A. Redmer) using alamarblue reagent (Serotec). Briefly, as previously described [2] , BAEC (2 3 10 4 cells/ml) were incubated in 24-well plates with D/F medium containing 10% FBS and 10% calf serum (16170-078; Gibco) at 378C in a humidified, 5% CO 2 in air for 14 h until the cells adhered to the wells. Subsequently, the media were changed to treatmentconditioning medium (TCM) that consisted of 30% LCM (see Cell culture treatment with cytokines) and 70% fresh D/F medium with no serum added. In negative controls, TCM was replaced by luteal cell culture medium alone, that is, without luteal cells, containing the same cytokine treatments used for the experimental treatments. Samples were run in triplicate and incubated for 48 h. The TCM was then removed and fresh phenol red-free D/F medium containing 10% alamarblue was added. The plates were incubated for a further 5 h and absorbance read at 570 and 600 nm (SpectrMax 340 PC; Molecular Devices). The optimal incubation time for BAEC with conditioned media from equine luteal cell cultures was 5 h because at this time a linear correlation between the percentage reduction of the indicator and cell density was optimal (R 2 ¼ 0.9507) based on calculations according to the manufacturer's instructions [2] . The percentage of viable BAEC after incubation with TCM was evaluated by comparing the percentage reduction of the media indicator with that produced by the negative controls (without luteal cells). Cell viability or mitogenesis in response to negative controls was considered to be 100% [2, 39] . Reduction or oxidation of the media indicator was evaluated by cellular GALVÃ O ET AL.
incorporation of the fluorimetric/colorimetric growth indicator [39] . Alamarblue percentage reduction using absorbance was determined according to the technical datasheet.
Cytokine effects on VEGF, VEGFR2, TSP1, and CD36 mRNA transcription. Cells isolated from different stages of the luteal phase (early CL, n ¼ 5; mid-CL, n ¼ 5; late CL, n ¼ 5) and treated with cytokines (24-well plates) were used (see Cell culture treatment with cytokines). For VEGF, VEGFR2, TSP1, and CD36 genes, specific primers were designed (Table 1) , following the guidelines for real-time PCR [40] .
Western blot analysis of VEGF. Quantification of VEGF protein expression by mid-CL cells incubated with cytokines was assessed by Western blot analysis after protein extraction from cells cultured in T25 culture flasks (see Cell culture treatment with cytokines). Radioimmunoprecipitation assay buffer (250 ll) (R0278; Sigma) with a protease inhibitor (complete), pH 7.4, was added to the cells. The cell concentration was determined, and 100 lg of protein were loaded on a 12% acrylamide gel (161-0155; Bio-Rad) for VEGF and b-actin quantification and subsequently transferred to nitrocellulose membranes (1620116; Bio-Rad) [20] . For VEGF detection, a rabbit polyclonal antibody (sc-152; Santa Cruz Biotechnology) diluted 1:200 was used, while for b-actin (A5441; Sigma), a mouse monoclonal antibody was used at 1:10 000 dilution. Membranes were further incubated overnight at 48C. The secondary antibodies used were horseradish peroxidase (HRP)-conjugated anti-rabbit (P0448; Dakocytomation) at 1:5000 for VEGF and HRP-conjugated goat anti-mouse (A2554; Sigma) for b-actin at 1:100 000, both incubated for 2.5 h at room temperature (238C). Protein expression was visualized by means of luminol-enhanced chemiluminescence (34077; Thermo Scientific) and exposure of the membrane to a blue lightsensitive autoradiography film (Kodak BioMax Light Film; Kodak-Industrie). Equal protein loading per lane was confirmed with b-actin. For protein expression quantification, target protein expression was normalized after dividing units of arbitrary densitometry for VEGF by the b-actin density for each band. Signals were densitometrically assessed using the ImageMaster 1D Elite densitometric analysis program (Amersham Biosciences).
Experiment 2. Evaluation of VEGF Effect on Luteal Cell Secretory Capacity
Cell culture treatment with VEGF: dose assessment. To determine the most effective dose of VEGF on luteal secretory activity, mid-CL cells were incubated with 0, 1, 10, or 50 ng/ml recombinant human VEGF (V7259; Sigma) in 24-well plates for 24 h. Equine LH (L9773; Sigma) (10ng/ml) was used as the positive control [20] . Conditioned media were stored at À808C for further analysis.
VEGF effect on P 4 and PGE 2 secretion. Mid-CL cell cultures (n ¼ 5) were incubated for 24 h at 378C in 5% CO 2 in air with no exogenous factor (control), 50 ng/ml VEGF, or 10 ng/ml LH (positive control) [20] . Conditioned media were stored at À808C until evaluation of P 4 and PGE 2 concentrations, and cells were treated with TRIZOL reagent and frozen in À808C for mRNA level quantification as described before.
VEGF effect on transcription of 3bHSD and PGES mRNA. Equine luteal cells from the previous experiment were used for 3bHSD and PGES mRNA transcription quantification. Specific primers were designed (Table 1) following the guidelines for real-time PCR [40] . Real-time PCRs were run, and the data were analyzed as previously described [20] .
Luteal Cell Viability and Proliferation Assessment
In all the in vitro studies, luteal cells were also plated in 96-well cell culture plates (Corning), and treated with the same factors as described before [20] . Briefly, cells at 1.0 3 10 4 /ml were incubated for 24 h at 378C in a humidified, 5% CO 2 in air. The cell viability was determined with Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (G3581; Promega) according to the manufacturer's manual at 490 nm.
Hormone Determinations
Concentrations of P 4 and PGE 2 in LCM and P 4 in plasma were determined by direct enzyme immunoassay (EIA). For P 4 evaluation, antiserum was used at a final dilution of 1:100 000, as described previously [41] . HRP-labeled P 4 was used at a final concentration of 1:75 000. The standard curve ranged from 0.39 to 100 ng/ml, and the concentration of P 4 at 50% binding (ED50) was 4.1 ng/ml. The intra-and interassay coefficients of variation (CV) were 5.5 % and 8.5 %, respectively.
Determination of PGE 2 concentrations followed the methodology described before [42] . The PGE 2 standard curve ranged from 0.39 ng/ml to 100 ng/ml, and the concentration at 50% binding (ED50) was 6.25 ng/ml. The intra-and interassay CV were 1.6% and 11.0%, respectively. Concentrations of hormones in culture media were normalized for the number of live cells after viability assessment. In viability assessment, the assay base line corresponded to the control level.
Statistical Analysis
Data were analyzed using one-way analysis of variance (ANOVA) followed by the Bonferroni multiple comparison test (GraphPAD PRISM, Version 5.00; GraphPad Software). Significance was defined as values of P , 0.05.
RESULTS
Cytokines were able to modulate angiogenesis activity by cells from equine CLs, which was indirectly determined by BAEC viability assessment. After culture of early CL cells, conditioned medium from TNF treatment increased BAEC viability (P , 0.05; Fig. 1a) , while conditioned medium from mid-CL cells treated with the cytokine combination TNFþIFNGþFASL reduced BAEC viability (P , 0.05; Fig.  1b ). In the conditioned medium generated from late CL cell culture, the treatments TNF and IFNG alone (P , 0.05; Fig.  1c ) or the combination of TNFþIFNGþFASL decreased BAEC viability (P , 0.01; Fig. 1c) . Regarding mRNA levels of cytokines and their receptors in CL cells, TNF increased VEGF and VEGFR2 mRNA in early CL cells (P , 0.05; Fig.  2a) , while all the other treatments reduced CD36 mRNA level (P , 0.001; Fig. 2a) . Cells from mid-CL incubated with TNF also exhibited an increase in VEGF mRNA (P , 0.05; Fig. 2b ) and a reduction of CD36 mRNA levels (P , 0.05; Fig. 2b) , as 
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seen in the previous stage. In late CL cells, treatments with TNF and TNFþIFNGþFASL were responsible for a fall in VEGFR2 mRNA level (P , 0.05; Fig. 2c ), whereas TNFþIFNGþFASL increased mRNA of both TSP1 and its receptor CD36 (P , 0.05; Fig 2c) . Analysis of VEGF protein expression by Western blots found an increase in VEGF expression when mid-CL cells were treated with TNF. In contrast, incubation of mid-CL cells with FASL and TNFþIFNGþFASL decreased VEGF protein expression (P , 0.05; Fig. 3 ).
The concentration of 50 ng/ml of VEGF was chosen as the most suitable for in vitro studies because this concentration increased P 4 production by isolated mid-CL cells (P , 0.05), while the other doses that were tested (1 and 10 ng/ml) did not produce any effect. Considering VEGF effects on P 4 and PGE 2 secretion, 24-h incubation of mid-CL cells with VEGF (50 ng/ml) or LH (10 ng/ml, positive control) stimulated the in vitro secretion of both P 4 (P , 0.05) and PGE 2 (P , 0.01) (Fig. 4) . Treatment with VEGF or LH for 24 h also increased the mRNA level of 3bHSD (P , 0.01) and PGES (P , 0.05; Fig. 5 ) in the same cells. The cytokines tested, either alone or in combination, had no effect on in vitro viability and proliferation of cells obtained from early CLs. However, the cytokine combination TNFþIFNGþFASL reduced luteal cell viability and proliferation in mid-(to 77.3% 6 3.1%) and late CL cells (to 57.8% 6 5.2%) (P , 0.05; Fig. 6a ). The effect of VEGF on isolated mid-CL cells was determined, and the viability and proliferation were increased by both VEGF (to 150.7% 6 12.7%) and LH treatments (to 154.1% 6 20.2%) (P , 0.05; Fig. 6b ).
DISCUSSION
The present study showed the interaction between cytokines (TNF, IFNG, and FASL) and angiogenic function in the equine CL. Moreover, the complexity of luteal function regulation in the mare, involving the relationship between the conserved angiogenic factor VEGF and luteal secretory function (P 4 and PGE 2 production), was also addressed.
Soon after ovulation, several cellular and biochemical processes triggered by LH, such as extracellular matrix remodeling and immunelike responses, lead to angiogenesis [10] . Among other factors, VEGF has been identified as the main angiogenic factor produced by luteal cells [43, 44] . At present, the precise effect of LH on VEGF production is not clear. The in vitro stimulatory effect of LH on VEGF secretion by granulosa cells seen in cows [45] and women [46] was less conclusive after in vivo studies in human and primates [47] , mice [48] , or cows [49] where it was found that VEGF was not increased by LH. These findings substantiate the complexity of luteal angiogenesis regulation. The ability of cytokines to modulate angiogenesis by equine luteal cells throughout the luteal phase was shown in the present work by assessing BAEC viability. Even though they represent a macrovascular model, BAEC were used. Unlike in the cow [50] , no adequate model to study microvascular angiogenesis in equine CL has been developed and validated so far. Microvascular or macrovascular endothelial cells produce different angiogenic responses to stimuli as shown by the ability of microvascular endothelium to form tubelike structures [51] . However, as previously demonstrated, because of their high degree of autocrine activity, BAECs were considered suitable for the study of angiogenesis modulators [52, 53] , and in previous studies, BAECs were used to screen in vitro angiogenic activity of luteal tissue [54] and endometria [55] .
The importance of immunelike responses on angiogenesis regulation in bovine CL [56] and other tissues from humans or mice [57, 58] has been established. Particularly, TNF and IFNG stimulated in vitro production of VEGF by human macrophages [59] . In a previous study on equine CL, cytokine TNF also stimulated angiogenic activity by CL tissue from the early luteal phase when used as a positive control [54] . In the present study, VEGF mRNA level was increased by TNF in the early and mid-CL phases as well as its receptor VEGFR2 in the early CL phase. Protein analysis also showed a stimulatory role of TNF on VEGF expression by mid-CL cells. When the inhibitory effect of TNF on the mRNA level of the antiangiogenic receptor CD36 in early CL cells is taken into consideration, these findings suggest that TNF might participate in angiogenesis at the time of luteal formation in the mare. Very few studies have reported the action of TNF or other cytokines on luteal VEGF production and angiogenesis. In fact, TNF stimulated VEGF secretion by cultured bovine granulosa cells [45] and by porcine mid-and late CL cells, when VEGFR2 mRNA was inhibited [60] . As presently demonstrated, TNF stimulation of VEGF mRNA level in early and mid- GALVÃ O ET AL. 
FIG. 4.
Mid-CL cells in vitro production of P 4 and PGE 2 after 24-h treatment with no exogenous factor ( control), VEGF (50 ng/ml), or LH (10 ng/ml). Bars represent mean 6 SEM. Asterisks indicate significant differences (*P , 0.05; **P , 0.01; ***P , 0.001).
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CL cells are lost in the late luteal phase. This may indicate the demise of a TNF proangiogenic effect toward the end of the luteal phase. These data disagree with other work reported for the sow [60] , which may indicate species specificities. Indeed, in the mare late CL cells, TNF, either alone or combined with other cytokines, reduced BAEC viability and VEGFR2 mRNA level. The ability of TNF to modulate angiogenesis in diverse ways was shown previously in different organs [61] , suggesting that TNF can act on different angiogenic-signaling pathways, depending on the particular biological system [62] .
Another cytokine studied, IFNG, has been described as an important regulator of luteal function [63] [64] [65] . Concerning angiogenesis control in the mare early CL in the present study, IFNG reduced the mRNA level of the antiangiogenic receptor CD36. In contrast, in the late CL, IFNG alone decreased angiogenic activity even though no changes were observed on VEGF protein expression or mRNA levels of TSP1 and CD36. This cytokine was associated with cellular senescence of cultured bovine luteal endothelial cells [21] , suggesting that IFNG may support the cytotoxic effect of TNF on luteal steroidogenic [66] and endothelial cells during bovine CL regression [23, 67] .
The role of FASL in equine luteal regression and CL secretory capacity modulation was recently described [20] . Besides inducing PGF 2a and inhibiting P 4 and PGE 2 secretion at the time of luteolysis, the present findings suggest that FASL may also suppress angiogenesis by reducing VEGF protein expression. This cytokine is known as a down-regulator of angiogenesis in different organs [68, 69] . However, to the best of our knowledge, this is the first report on VEGF expression modulation by FASL in the equine CL. Discrepancies between mRNA level and protein expression suggest that VEGF gene regulation by FASL does not depend solely on transcriptional control of its mRNA. In fact, posttranscriptional regulation includes other steps such as processing, export, localization, turnover, and translation of mRNAs, highlighting the com- GALVÃ O ET AL. plexity of gene expression control [70] . Here, we could speculate about the role of RNA-binding proteins in the regulation of transcript fates [71] . Small interfering RNAs and micro-RNAs, in association with protein effector complexes, can also control both degradation and translation of target transcripts [72] . Thus, FASL and TNFþIFNGþFASL appear to regulate VEGF protein expression in luteal cells through a down-regulation of protein translation, besides expression of its mRNA.
When all the cytokines were tested together (i.e., TNFþIFNGþFASL), angiogenesis restriction was very effective, mainly in mid-and late CL cells. In late CL cells, both TSP1 and CD36 mRNA levels were increased, while VEGFR2 was reduced. Although no changes were seen in mRNA level, the same cytokine combination also reduced VEGF protein expression in mid-CL cells. A previous study on the bovine CL also showed that this cytokine combination appeared to be a determinant for angiogenesis regression [11] . In the mare, early luteolysis induced after administration of PGF 2a in vivo was associated with a decrease in VEGF mRNA and protein expression as well as a reduction in endothelial cell proliferation in the CL [27] . More recently, in vitro studies on the equine CL showed that during luteolysis, PGF 2a also decreased endothelial cell proliferation, suggesting that this hormone may be involved in vascular regression [1] . In the present study, we showed the importance of cytokines TNF, IFNG, and FASL in luteal angiogenesis modulation through VEGF down-regulation.
The hypothetical role of VEGF in the secretory capacity of equine CL was also addressed. Because VEGF expression remains high until Day 10 of the luteal phase in the mare [27] , when CL vasculature is fully developed [73] , another role in luteal regulation other than angiogenic function may be indicated. It was shown that in vivo VEGF inhibition in marmosets at the time of luteal establishment and in macaques during the midluteal phase reduced plasma levels of P 4 [35, 74] . Because the microvascular tree was already complete, this plasma P 4 drop after VEGF inhibition cannot be related to angiogenesis. However, it may indicate a role of VEGF on blood vessel survival and permeability maintenance, where VEGF is needed for access of LH and low-density lipoprotein cholesterol to luteal steroidogenic cells for P 4 synthesis [35] . Moreover, infusion of VEGF stimulated in vitro P 4 secretion by bovine early CL cells [75] . In the present study, we confirmed that VEGF could effectively modulate luteal secretory function. To the best of our knowledge, we have shown for the first time that VEGF increases P 4 and PGE 2 secretion from mare mid-CL cells, as well as mRNA levels of 3bHSD and PGES. However, considerable differences were found in the magnitude of mRNA level in the cells and P 4 quantification in culture media. The P 4 synthesis pathway requires participation of other enzymes, such as steroidogenic acute regulatory protein [76] and cytochrome P450 side chain cleavage enzyme [reviewed in 77]. Thus, VEGF should promote steroidogenesis by also acting on other enzymes besides 3bHSD, which can explain the disparity found between the 3bHSD mRNA level and the amount of P 4 production. Concerning P 4 action in the CL, its prosurvival role and ability to prevent apoptosis in an auto/paracrine way are well established [78, 79] . Thus, it is suggested that VEGF, a prosurvival factor [80] , could stimulate the secretion of P 4 and PGE 2 , which via an auto/paracrine pathway may support luteal establishment and maintenance.
In conclusion, the present findings suggest a novel auto/ paracrine action of cytokines on equine luteal function modulation. Specifically, TNF may up-regulate VEGF and stimulate angiogenesis in the mare early CL. In addition, VEGF has been shown to stimulate P 4 and PGE 2 production, which might also indicate a role in luteal establishment. In contrast, at luteolysis the cytokines TNF, IFNG, and FASL may contribute to angiogenesis down-regulation. However, further studies are needed to achieve a better understanding of these regulatory mechanisms, especially concerning the specific role of equine luteal endothelial cells.
